MRK Merck & Company Inc. (new)
73.08
-0.11 -0%
Previous Close
73.19
Open
73.16
Price To Book
7.07
Market Cap
188771128162
Shares
2,583,075,098
Volume
4,955,966
Short Ratio
3.36
Av. Daily Volume
10,413,680
NewsSee all news
- Merck's Keytruda wins FDA approval as combination therapy for kidney cancer
- FDA Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination With Inlyta® (axitinib) as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma (RCC)
- The Top 10 Biotechnology Companies (JNJ, ROG.VX)
- Pharmaceutical ETFs Catch Healthcare Contagion
- Keeley Funds Comments on Versum Materials
Drug Information
Drug catalyst information is displayed when you hover over the stage bar graph.
FDA Approval announced February 19, 2019.
KEYTRUDA - EORTC1325/KEYNOTE-054
Melanoma
Approval announced June 13, 2018.
Keytruda
Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL)
FDA approval (label expansion) announced June 5, 2018.
KEYTRUDA + chemo (KEYNOTE-021)
First-Line Nonsquamous Non-small cell lung cancer (NSCLC)
Phase 3 trial did not meet primary endpoint - July 24, 2017. Awarded accelerated approval in 2016.
KEYNOTE-040 KEYTRUDA
Recurrent or metastatic head and neck squamous cell carcinoma (HNSCC)
LUSDUNA Nexvue
Diabetes
Phase 3 clinical hold announced July 6, 2017.
KEYTRUDA - KEYNOTE-183
Multiple myeloma
Phase 3 clinical hold announced July 6, 2017.
KEYTRUDA - KEYNOTE-185
Multiple myeloma
Approved Sept. 22, 2017 under accelerated approval in patients undergoing third-line treatment following data from Phase 2 Keynote-59 trial. Phase 3 data released December 14, 2017 in patients undergoing second-line treatment, did not meet the primary endpoint of overall survival, nor did it show a significant improvement in PFS.
Keytruda
Cancer - Third-line Gastric or Gastroesophageal Junction Adenocarcinoma
Phase 1/2 various presentations at ASCO June 5, 2017. Updated data at ESMO Saturday, 9 September 2017 showed ORR 56% in melanoma patients.
Epacadostat with Keytruda - ECHO-202/KEYNOTE-037
NSCLC, RCC, Triple-Negative Breast, Ovarian, Urothelial Carcinoma, Solid Tumors
CRL issued April 7 2017. sNDA for approved drug requested to include data on cardiovascular effects
Januvia (Sitagliptin)
Type 2 Diabetes
Approved March 1, 2017.
Odactra (MK-8237)
House dust mite allergies
PIFELTRO (doravirine)
HIV
Approved May 18, 2017.
KEYTRUDA
First and Second line locally advanced or metastatic urothelial cancer - bladder cancer
FDA label expansion announced January 31, 2019.
(MK-3475-189/KEYNOTE-189)
First Line Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)
Approval announced December 20, 2017.
Ertugliflozin
Type 2 diabetes
Phase 3 interim analysis by DMC advised trial to be discontinued due to lack of benefit vs risk.
MK-8931 (019) - Verubecestat
Mild-to-moderate Alzheimer's
Approval announced November 9, 2017.
Letermovir
Cytomegalovirus (CMV) Infection
Phase 3 trial stopped due to lack of efficacy - February 14, 2017.
MK-8931 (017) - Verubecestat
Mild-to-moderate Alzheimer's
Phase 3 trial met its primary endpoint - October 2016. Updated data presented at ASCO 2017. HR 0.70. OS 10.3 months.
Keytruda - KEYNOTE-045
Bladder Cancer
Phase 3 planned.
Epacadostat with Keytruda
Non-small cell lung cancer (NSCLC)
Phase 3 planned.
Epacadostat with Keytruda -
Bladder cancer
Phase 3 planned.
Epacadostat with Keytruda -
Cancer - squamous cell carcinoma of the head and neck
Phase 3 data due released June 27, 2017. Primary endpoint met but noted August 29, 2017 that key secondary endpoint was not met. Announced October 11, 2017 that it will not seek regulatory approval.
Anacetrapib (MK-0859)
Raising HDL-C and reducing LDL-C
Approved May 10, 2017.
Keytruda
First-Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer
Approval announced March 14, 2017.
KEYTRUDA
Relapsed or Refractory Classical Hodgkin Lymphoma
PDUFA date March 8, 2017 extended to June 9, 2017 due to submission of extra data. Approved May 23, 2017.
KEYTRUDA
Microsatellite Instability-High Cancer
BLA acceptance announced May 23, 2016 by partner Samsung Bioepis. Approval annuonced April 21, 2017.
RENFLEXIS - SB2 (infliximab biosimilar)
Biosimilar candidate of Remicade
Approval announced May 30, 2017.
ISENTRESS
HIV-1
FDA Approval announced December 19, 2018.
Lynparza - SOLO 1
First-line ovarian cancer following platinum-based chemotherapy
Phase 3 data released February 17, 2016 - primary endpoint met. Late breaker at ASCO June 4, 2017 showed HR of 0.58 (42% reduction of risk of disease progression or death). Approval announced January 12, 2018.
Lynparza
Breast cancer
Phase 3 trial did not meet primary endpoint - noted April 6, 2018.
Epacadostat with Keytruda - ECHO-301
Cancer - first-line metastatic melanoma.
Approval announced June 12, 2018.
KEYTRUDA
Cervical cancer
Phase 3 data released February 26, 2019 - PFS primary endpoint met.
Lynparza
Pancreatic cancer
FDA Approval announced April 11, 2019.
Keytruda - KEYNOTE-042
Non-small cell lung cancer (NSCLC)
Phase 3 data due 2020.
Lynparza - OlympiA
HER2-negative breast cancer
FDA approval announced October 30, 2018.
KEYTRUDA + carboplatin-paclitaxel or nab-paclitaxel KEYNOTE-407
Squamous non-small cell lung cancer (sNSCLC)
Approval announced October 5, 2018.
GARDASIL 9
Human Papilloma virus vaccine
Phase 3 data February 19, 2019 did not meet primary endpoints.
Keytruda KN-240
Hepatocellular Carcinoma
Keytruda KN-048
Head and neck squamous cell carcinoma (HNSCC)
FDA approval announced November 9, 2018.
Keytruda - KEYNOTE-224
Hepatocellular carcinoma (HCC)
FDA approval announced August 16, 2018.
LENVIMA (lenvatinib)
Hepatocellular Carcinoma (HCC)
FDA Approval announced December 19, 2018.
Keytruda KN-17
Merkel Cell Carcinoma
ZERBAXA(ceftolozane and tazobactam)
Hospital-acquired bacterial pneumonia (HABP)
Phase 1 data at ESMO October 2018 noted zero responses in monotherapy arm, 24% with Keytruda.
MK-1454 - STING
Solid tumors
KEYTRUDA and Inlyta - KEYNOTE-426
Renal cell carcinoma
Phase 3 trial did not meet primary endpoint of OS in intend-to-treat population. Endpoint met in squamous cell carcinoma or adenocarcinoma groups.
Keytruda KN-181
Esophageal Cancer
LENVIMA (lenvatinib) + Keytruda - KN-581
Renal cell carcinoma (RCC) - cancer
Rolling BLA filing has commenced - noted November 13, 2018.
V920
Ebola
DELSTRIGO (doravirine/lamivudine/tenofovir disoproxil fumarate)
HIV
Imipenem/ cilastatin
Complicated urinary tract infections (cUTI) and Complicated intra-abdominal infections (cIAI)
Latest News
- Merck's Keytruda wins FDA approval as combination therapy for kidney cancer
- FDA Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination With Inlyta® (axitinib) as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma (RCC)
- The Top 10 Biotechnology Companies (JNJ, ROG.VX)
- Pharmaceutical ETFs Catch Healthcare Contagion
- Keeley Funds Comments on Versum Materials
- Clovis Focuses on Rubraca Label Expansion, Competition Stiff
- Can Q1 Earnings Lift Healthcare ETFs Higher?
- Here Are the Key Takeaways From J&J's Q1 Earnings Report
- Novo Nordisk's (NVO) Share Price Rises YTD on Strong Pipeline
- EMD FINANCE LLC -- Moody's affirms Merck KGaA's ratings; stable outlook
- Bristol-Myers Squibb Company -- Moody's assigns A2 to Bristol-Myers's exchange notes; under review for downgrade
- Top Analyst Reports for Wells Fargo, UnitedHealth & Merck
- Gilead Collaborates With Insitro to Develop NASH Therapies
- 3 Charts That Suggest Health Care Stocks Are Headed Lower
- J&J (JNJ) Beats on Q1 Earnings, Ups 2019 Sales Growth View
- Why Merck (MRK) is a Top Dividend Stock for Your Portfolio
- The Daily Biotech Pulse: J&J Earnings, FDA Nod For Medicinova, Proteon To Explore Strategic Alternatives
- Merck Financial Services GmbH -- Moody's affirms Merck KGaA's ratings; stable outlook
- Merck (MRK) Dips More Than Broader Markets: What You Should Know
- Bristol-Myers' Shareholders Vote for Celgene Acquisition